AIDS Therapies

Drug Already in Human Tests Embodies New Anti-HIV Strategy

Published in AIDS Weekly, August 11th, 1997

U.S. researchers developing a new approach to AIDS drugs have found that their strategy is already being tested in European clinical trials.

The novel, rational approach to new anti-HIV agents focuses on two zinc-binding domains of the HIV nucleocapsid p7 (NCp7) protein, which are extraordinarily well-conserved among viral strains. William G. Rice of the National Cancer Institute and colleagues have been developing compounds that attack the sulfur atoms of the cysteine residues that coordinate zinc binding (Rice et al., Nature, 1993;361:473-5; PNAS, 1993;90:9721-4; Science, 1995;270:1194-7; Antimic Ag Chem, 1997;41:419-26).

Meanwhile, M. Vandevelde...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1997-08-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry